Alzamend Neuro, Inc.

NasdaqCM:ALZN Stock Report

Market Cap: US$6.2m

Alzamend Neuro Management

Management criteria checks 4/4

Alzamend Neuro's CEO is Stephan Jackman, appointed in Nov 2018, has a tenure of 6.25 years. total yearly compensation is $443.62K, comprised of 78.9% salary and 21.1% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth $344.08. The average tenure of the management team and the board of directors is 5.8 years and 3.7 years respectively.

Key information

Stephan Jackman

Chief executive officer

US$443.6k

Total compensation

CEO salary percentage78.9%
CEO tenure6.3yrs
CEO ownership0.006%
Management average tenure5.8yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Jul 26
Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Mar 20
Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate

Oct 14
We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Oct 05

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Sep 29

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Jul 18

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 18

Alzamend Neuro closes $14.4M IPO

Jun 17

CEO Compensation Analysis

How has Stephan Jackman's remuneration changed compared to Alzamend Neuro's earnings?
DateTotal CompensationSalaryCompany Earnings
Oct 31 2024n/an/a

-US$6m

Jul 31 2024n/an/a

-US$7m

Apr 30 2024US$444kUS$350k

-US$10m

Jan 31 2024n/an/a

-US$12m

Oct 31 2023n/an/a

-US$15m

Jul 31 2023n/an/a

-US$15m

Apr 30 2023US$2mUS$300k

-US$15m

Jan 31 2023n/an/a

-US$15m

Oct 31 2022n/an/a

-US$13m

Jul 31 2022n/an/a

-US$13m

Apr 30 2022US$473kUS$303k

-US$12m

Jan 31 2022n/an/a

-US$10m

Oct 31 2021n/an/a

-US$8m

Jul 31 2021n/an/a

-US$6m

Apr 30 2021US$225kUS$225k

-US$5m

Jan 31 2021n/an/a

-US$5m

Oct 31 2020n/an/a

-US$5m

Jul 31 2020n/an/a

-US$5m

Apr 30 2020US$2mUS$188k

-US$4m

Jan 31 2020n/an/a

-US$4m

Oct 31 2019n/an/a

-US$4m

Jul 31 2019n/an/a

-US$4m

Apr 30 2019US$3mUS$50k

-US$5m

Compensation vs Market: Stephan's total compensation ($USD443.62K) is below average for companies of similar size in the US market ($USD640.92K).

Compensation vs Earnings: Stephan's compensation has been consistent with company performance over the past year.

CEO

Stephan Jackman (48 yo)

6.3yrs

Tenure

US$443,617

Compensation

Mr. Stephan Jackman has been Chief Executive Officer of Alzamend Neuro, Inc. since November 20, 2018 and has been its Director since September 2020. Mr. Jackman has experience in administration, business a...

Leadership Team

NamePositionTenureCompensationOwnership
Stephan Jackman
CEO & Director6.3yrsUS$443.62k0.0056%
$ 344.1
Milton Ault
Founder & Vice Chairman1.1yrsUS$8.33k0.31%
$ 18.9k
David Katzoff
Chief Financial Officer2.5yrsUS$150.00k0.0099%
$ 612.9
Henry C. Nisser
Executive VP5.8yrsUS$50.00k0%
$ 0
Kenneth Cragun
Senior Vice President of Finance3.7yrsno data0%
$ 0

5.8yrs

Average Tenure

55yo

Average Age

Experienced Management: ALZN's management team is seasoned and experienced (5.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stephan Jackman
CEO & Director4.4yrsUS$443.62k0.0056%
$ 344.1
Milton Ault
Founder & Vice Chairman1.1yrsUS$8.33k0.31%
$ 18.9k
Henry C. Nisser
Executive VP4.4yrsUS$50.00k0%
$ 0
William Horne
Chairman of the Board8.7yrsUS$50.00k0.12%
$ 7.6k
Mark Gustafson
Independent Director3.7yrsUS$25.00k0.0074%
$ 453.8
Lynne McGrath
Independent Director3.7yrsUS$25.00k0.0092%
$ 567.3
Thomas Wisniewski
Member of Scientific Advisory Board5.6yrsno datano data
Eric McDade
Member of Scientific Advisory Boardno datano datano data
Jeffrey Oram
Independent Director3.7yrsUS$25.00k0.012%
$ 756.0
Andrew Woo
Independent Director3.7yrsUS$25.00k0.012%
$ 756.0
Terri Hunter
Member of Scientific Advisory Board2.8yrsno datano data

3.7yrs

Average Tenure

56.5yo

Average Age

Experienced Board: ALZN's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 21:42
End of Day Share Price 2025/01/31 00:00
Earnings2024/10/31
Annual Earnings2024/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alzamend Neuro, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC